Alcami Corporation, a contract development and manufacturing organization (CDMO), reported the recent announcement by Nectero Medical that they have received clearance from the U.S. Food and Drug Administration (FDA) of their investigational new drug (IND) application to initiate Phase II/III trial of the Nectero Endovascular Aneurysm Stabilization Treatment (EAST) System for the treatment of small- to-mid-sized abdominal aortic aneurysms (AAA). Nectero Medical is developing a novel treatment...